Ipsen to acquire Kartos Therapeutics for up to $1.75 billion

TL;DR

Reports differ across sources; according to finance.yahoo.com, ipsen agreed to acquire Kartos Therapeutics, a Redwood City, California-based clinical-stage biopharmaceutical company developing a treatment for myelofibrosis, a rare blood cancer, for $450 million upfront and up to $1.3 billion in additional milestone payments, bringing the total potential deal value to $1.75 billion.